The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
The companies clash over survival curve similarities – and differences.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
NXP800 yields neither severe thrombocytopenia, nor any responses.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
